Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 10/20 | 0.67 |
| ▸ | ACE2 | Q9BYF1 | 6/20 | 0.60 |
| ▸ | ACE | P12821 | 5/20 | 0.60 |
| ▸ | CPA1 | P15085 | 5/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17624791 | 0.90 | MME (0.56) | MMEACE2ACECPA1NAALAD2 | |
| SCHEMBL14958858 | 0.89 | MME (0.61) | MMEACE2ACECPA1NPSR1 | |
| SCHEMBL3785458 | 0.88 | MME (0.60) | MMEACE2ACECPA1NPSR1 | |
| SCHEMBL3785447 | 0.88 | MME (0.60) | MMEACE2ACECPA1NPSR1 | |
| SCHEMBL12341129 | 0.88 | MME (0.60) | MMEACE2ACECPA1NPSR1 | |
| SCHEMBL3785450 | 0.88 | MME (0.60) | MMEACE2ACECPA1NPSR1 | |
| SCHEMBL31390164 | 0.87 | MME (0.63) | MMEACE2ACECPA1 | |
| SCHEMBL31390141 | 0.87 | MME (0.63) | MMEACE2ACECPA1 | |
| SCHEMBL11414321 | 0.86 | MME (0.61) | MMEACE2ACECPA1NPSR1 | |
| SCHEMBL11414316 | 0.86 | MME (0.61) | MMEACE2ACECPA1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9795678-B2 | Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound | ADOCIA (FR) | 2017-10-24 | — | — | US | disclosed |
| US-20160082106-A1 | Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound | ADOCIA (FR) | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160082106-A1 | Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound | IAPP, GPR119, INSR | MME 1692/4885ACE2 2043/4885ACE 849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.